
CLAIMS

1. Use of a coagulation inhibiting amount of a compound of Formula II:



II


or a pharmaceutically acceptable salt thereof, in the preparation of a pharmaceutical composition for inhibiting coagulation in a human patient in need thereof, wherein the composition is for administration to the patient once a day, and the coagulation inhibiting amount of the compound is between 0.4 and 1.2 mg/kg.

2. The use according to claim 1, wherein the coagulation inhibiting amount of the compound is between 0.43 and 1.15 mg/kg.

3. The use according to claim 1, wherein the coagulation inhibiting amount of the compound is between 0.45 and 0.55 mg/kg.

4. The use according to any one of claims 1-3, wherein the pharmaceutically acceptable salt of the compound is a maleate salt.

5. Use of a coagulation inhibiting amount of a compound of Formula II:



II

or a pharmaceutically acceptable salt thereof, in the preparation of a pharmaceutical composition for inhibiting coagulation in a human patient in need thereof, wherein the composition is for administration to the patient, and the coagulation inhibiting amount of the compound is between about 30 and 80 mg per day.

6. The use according to claim 5, wherein the coagulation inhibiting amount of the compound is about 30 mg per day.

7. The use according to claim 5, wherein the coagulation inhibiting amount of the compound is about 80 mg per day.

8. The use according to any one of claims 5-7, wherein the pharmaceutically acceptable salt of the compound is a maleate salt.